Description:
The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or
recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and
pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse
Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors
for whom no further effective standard treatment is available.
Title
- Brief Title: Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
- Official Title: A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies
Clinical Trial IDs
- ORG STUDY ID:
CMAK683X2101
- SECONDARY ID:
2016-001860-12
- NCT ID:
NCT02900651
Conditions
- Diffuse Large B-cell Lymphoma
Interventions
Drug | Synonyms | Arms |
---|
MAK683 | | Phase I - All |
Purpose
The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or
recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and
pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse
Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors
for whom no further effective standard treatment is available.
Detailed Description
The purpose phase I of this trial is to characterize safety and tolerability and determine
the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of MAK683.
The purpose of the phase II of this trial will be to evaluate the anti-tumor activity of
MAK683.
Trial Arms
Name | Type | Description | Interventions |
---|
Phase I - All | Experimental | advanced stage (relapsed/refractory or recurrent/metastatic) malignancy limited to the following malignancies; DLBCL, nasopharyngeal carcinoma, gastric cancer, ovarian cancer, prostate cancer and sarcoma. | |
Eligibility Criteria
Inclusion Criteria:
1. Eastern Cooperative Oncology Group (ECOG): 0 to 2
2. Relapsed or refractory diffuse large B cell lymphoma with measurable disease as
determined by Non-Hodgkin's Lymphoma Cheson response criteria (2014)
3. Advanced or recurrent/metastatic solid tumor, including nasopharyngeal carcinoma,
castration-resistant prostate cancer, gastric cancer, ovarian clear cell carcinoma and
sarcoma, with measurable disease as determined by RECIST 1.1.
Exclusion Criteria:
1. Other malignant diseases than the ones being treated in this study
2. Severe and/or uncontrolled medical conditions that in the investigator's opinion could
affect the safety of individual or impair the assessment of study result.
3. B-cell lymphoma patients who have received prior allogeneic stem cell transplant
4. Patient have received anti-cancer therapies within defined time frames prior to the
first dose of study treatment
5. Symptomatic central nervous system (CNS) involvement which are neurologically unstable
or requiring increasing doses of steroids to control.
6. Patient having out of range laboratory values defined as:
1) Insufficient bone marrow function at screening:
- Platelets ≤ 50,000/mm3
- Hemoglobin (Hgb) ≤ 80 g/L
- Absolute neutrophil count (ANC) ≤ 1000/mm3 2) Insufficient hepatic and renal function
at screening:
- ALP, ALT, and AST > 3 x ULN (>5 x ULN if subject has liver metastases)
- Total bilirubin >1.5 x ULN
- Serum creatinine > 1.5 x ULN and/or creatinine clearance ≤ 50 mL/min
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Incidence of dose limiting toxicities (DLTs) |
Time Frame: | up to 28 days |
Safety Issue: | |
Description: | Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) |
Secondary Outcome Measures
Measure: | Overall Response Rate (ORR) |
Time Frame: | up to 30 months |
Safety Issue: | |
Description: | |
Measure: | Duration of overall response (DOR) |
Time Frame: | up to 30 months |
Safety Issue: | |
Description: | |
Measure: | Progression-free survival (PFS) |
Time Frame: | up to 30 months |
Safety Issue: | |
Description: | |
Measure: | Best Overall Response (BOR) |
Time Frame: | up to 30 months |
Safety Issue: | |
Description: | |
Measure: | Peak Plasma Concentration (Cmax) of MAK683 |
Time Frame: | 30 months |
Safety Issue: | |
Description: | Pharmacokinetic profile of MAK683 |
Measure: | Area Under the Plasma Concentration (AUC) Time Curve of MAK683 |
Time Frame: | 30 months |
Safety Issue: | |
Description: | Pharmacokinetic profile of MAK683 |
Measure: | Half-Life of MAK683 |
Time Frame: | 30 months |
Safety Issue: | |
Description: | Pharmacokinetic profile of MAK683 |
Measure: | H3K27 tri methylation level in PBMC |
Time Frame: | up to day 15 |
Safety Issue: | |
Description: | Cycle 1 Day 1,8,15 Cycle 2 Day1 Cycle 3 Day 1 End of treatment (EOT); Disease progression PBMC: peripheral blood mononuclear cell |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Novartis Pharmaceuticals |
Trial Keywords
- MAK683, DLBCL, EED - Embryonic ectoderm development, EZH2 - Enhancer of zeste homolog 2
Last Updated
July 27, 2021